Editor's choice
Scan to access more
free content

Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers

Laura Stumm,¹ Lia Burkhardt,¹ Stefan Steurer,¹ Ronald Simon,¹ Meike Adam,² Andreas Becker,² Guido Sauter,¹ Sarah Minner,¹ Thorsten Schlomm,^{2,3} Hüseyin Sirma,¹ Uwe Michl²

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jclinpath-2012-201335>).

¹Institute of Pathology, University Medical Center, Hamburg-Eppendorf, Germany

²Martini Clinic, Prostate Cancer Center, University Medical Center, Hamburg-Eppendorf, Germany

³Department of Urology, Section for Translational Prostate Cancer Research, University Medical Center, Hamburg-Eppendorf, Germany

Correspondence to

Uwe Michl, Martini-Clinic, Prostate Cancer Center, University Medical Center, 20246, Hamburg-Eppendorf, Germany; michl@uke.de

Received 6 November 2012

Revised 31 December 2012

Accepted 4 February 2013

Published Online First

4 April 2013

ABSTRACT

Background and aims Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before. The relevance and role of neuronal transcription factor FOXP2 in prostate cancer is unknown.

Methods A tissue microarray containing samples from more than 11 000 prostate cancers from radical prostatectomy specimens with clinical follow-up data was analysed for FOXP2 expression by immunohistochemistry. FOXP2 data were also compared with pre-existing ERG fusion (by fluorescence in situ hybridisation and immunohistochemistry) and cell proliferation (Ki67 labelling index) data.

Results There was a moderate to strong FOXP2 protein expression in basal and secretory cells of normal prostatic glands. As compared with normal cells, FOXP2 expression was lost or reduced in 25% of cancers. Strong FOXP2 expression was linked to advanced tumour stage, high Gleason score, presence of lymph node metastases and early tumour recurrence ($p < 0.0001$; each) in ERG fusion-negative, but not in ERG fusion-positive cancers. High FOXP2 expression was linked to high Ki67 labelling index ($p < 0.0001$) in all cancers irrespective of ERG fusion status.

Conclusions These data demonstrate that similar high FOXP2 protein levels as in normal prostate epithelium exert a 'paradoxical' oncogenic role in 'non fusion-type' prostate cancer. It may be speculated that interaction of FOXP2 with members of pathways that are specifically activated in 'non fusion-type' cancers may be responsible for this phenomenon.

INTRODUCTION

Transcription factors of the forkhead box P (FOXP1-4) family have been implicated in various human cancer types before.¹ For example, FOXP1 is a tumour suppressor in breast cancer² and has been suggested to play a role in prostate cancer also.³ FOXP3 is strongly expressed in tumour invading regulatory T cells and in lymphomas.⁴ FOXP4 expression is downregulated in kidney cancer⁵ and inactivated by translocation in several breast cancer cell lines.⁶ In a recent study, FOXP2 has also been implicated with cancer. Campbell *et al*⁷ found FOXP2 overexpression as a strong discriminator between normal lymphocytes and multiple myeloma. Apart from this, FOXP2 is known to have a role in neuronal differentiation. Specifically, FOXP2 was shown as a factor

influencing speech development.⁸ Apart from this one study in lymphoma, the role of FOXP2 expression in cancer has not been evaluated.

To determine, whether FOXP2 expression might have a role in prostate cancer, we made use of a prostate cancer tissue microarray (TMA) containing samples from more than 11 000 patients with follow-up information and an attached molecular database. The data show that FOXP2 expression is often either lost/reduced or increased in prostate cancer and that FOXP2 expression is significantly linked to tumour aggressiveness, especially in non-fusion type prostate cancer.

METHODS

Patients

A TMA was made from 11 152 prostatectomy specimens from patients undergoing surgery between 1992 and 2011 at the Department of Urology, and the Martini Clinics at the University Medical Center Hamburg-Eppendorf. The TMA manufacturing process was described earlier in detail.⁹ In short, one 0.6 mm core was taken from a representative tissue block from each patient. The tissues were distributed among 24 TMA blocks, each containing 129–522 cores. Clinical follow-up data were available for 9695 of the 11 152 arrayed tumours. Median follow-up was 36.8 months ranging from 1 month to 219 months. None of the patients received neoadjuvant endocrine therapy. Additional (salvage) therapy was only initiated after biochemical relapse, the clinical endpoint of this study. Prostate specific antigen values were measured following surgery and recurrence was defined as a postoperative prostate specific antigen (PSA) of 0.2 ng/ml and increasing thereafter. The detailed composition of the TMA and the attached histopathological and clinical data is outlined in table 1. Presence or absence of cancer tissue was validated by immunohistochemical AMACR and 34BE12 analysis.¹⁰ More than 50 tissue spots containing normal prostate glands were also included on the TMA. The molecular database attached to this TMA contained results on ERG expression in 9628 tumours and ERG breakapart fluorescence in situ hybridisation (FISH) analysis in 6106 tumours (extended from¹¹), as well as Ki67 labelling index (LI) in 7019 cancers (extended from¹⁰).

Immunohistochemistry

Freshly cut TMA sections were analysed in 1 day and in one experiment. The antibody anti-FOXP2

To cite: Stumm L, Burkhardt L, Steurer S, *et al*. *J Clin Pathol* 2013;**66**:563–568.

Table 1 Composition of the prognosis tissue microarray (TMA) containing 10 152 prostate cancer specimens

	Number of patients (%)	
	Study cohort on TMA (n=11152)	Biochemical relapse among categories (n=1824)
Follow-up (months)		
Mean	53.4	–
Median	36.8	–
Age (years)		
<50	318	49
50–60	2.768	460
60–70	6.548	1.081
>70	1.439	232
Pretreatment PSA (ng/ml)		
<4	1.407	142
4–10	6.735	827
10–20	2.159	521
>20	720	309
Tumour stage		
pT2	7.370	570
pT3a	2.409	587
pT3b	1.262	618
pT4	63	49
Gleason grade		
<3+3	2.859	193
3+4	1.565	573
4+3	6.183	849
>4+4	482	208
Lymph node metastasis		
pN0	6.117	1.126
pN+	561	291
Surgical margin		
Negative	8.984	1.146
Positive	1.970	642

Numbers do not always add up to 11 152 in the different categories because of cases with missing data.

(rabbit polyclonal, Sigma-Aldrich, St Louis, Missouri, USA; 1/60 dilution; cat#HPA000382) was used for detection of FOXP2 expression. Slides were deparaffinised and exposed to heat-induced antigen retrieval for 5 min in an autoclave at 121°C in pH 9 buffer. Bound primary antibody was visualised using the DAKO EnVision Kit (Dako). Staining was predominantly nuclear and its intensity was estimated in a 4-step scale as negative, weak, moderate and strong staining.

Statistics

For statistical analysis, the JMP V.9.0 software (SAS Institute Inc, North Carolina, USA) was used. Contingency tables were calculated to study the association between FOXP2 expression and clinicopathological variables, and the χ^2 (likelihood) test was used to find significant relationships. Kaplan-Meier curves were generated for PSA recurrence-free survival. The logrank test was applied to test the significance of differences between stratified survival functions. Cox proportional hazards regression analysis was performed to test the statistical independence and significance between pathological, molecular and clinical variables.

RESULTS

Technical aspects

TMA blocks with a total of 2088 tissue spots were excluded from the analysis due to insufficient immunohistochemistry (IHC) quality. FOXP2 analysis was successful in 8289 of the remaining 9064 arrayed cancers (91%). IHC was not interpretable in 775 (9%) tumours because lack of unequivocal tumour cells in the tissue spots or missing tissue spots on the TMA section.

FOXP2 expression in normal prostate epithelium and in prostate cancer

Intensity of FOXP2 immunostaining was moderate to strong in normal prostate epithelium and exclusively seen in the nucleus. Nuclei of basal and secretory cells were labelled, whereas no staining was seen in stromal cells. FOXP2 expression intensity was often reduced in prostate cancer as compared with normal epithelium (figure 1). FOXP2 immunostaining was found in 7779 of the 8289 analysable tumours (94%), including 1572 (19%) tumours with weak, 2846 (34%) with moderate and 3361 (41%) tumours with strong staining (table 2). Representative images are shown in figure 1. Strong FOXP2 positivity was significantly linked to advanced tumour stage, high Gleason grade and presence of lymph node metastases ($p<0.0001$; each). A subset analysis in 4206 ERG fusion-negative and 3096 ERG fusion-positive cancers with FOXP2 IHC data revealed that all associations of FOXP2 with unfavourable tumour phenotype were particularly strong in ERG-negative cancers ($p<0.0001$; each), but were completely lost in ERG-positive tumours. All associations of FOXP2 in all tumours and in ERG-positive and ERG-negative subgroups are summarised in table 2 and online supplementary tables S1–2.

Tumour cell proliferation (Ki67LI)

Strong FOXP2 staining was significantly linked to increased cell proliferation as measured by Ki67LI in all cancers (figure 2A; $p<0.0001$). This association was independent of the ERG fusion status (figure 2B,C; $p<0.0001$; each). This association was also independent from the Gleason grade, since it held also true if tumours of identical grade were separately analysed (figure 3). Overall, these data suggest a role of FOXP2 for tumour growth in general and a direct involvement in proliferation in particular.

TMPS2-ERG fusion status and ERG protein expression

The relationship of FOXP2 expression and 'fusion-type' prostate cancer was analysed by two independent methods. There were subsets of 4613 cancers with available TMPS2-ERG fusion data obtained by FISH and there were 7302 cancers with FOXP2 and ERG IHC data. Strong FOXP2 immunostaining was more frequent in ERG IHC-positive cancers (1826/3096; 59%) as compared with ERG IHC-negative cancers (1177/4206 (28%), $p<0.0001$, figure 4A). Genomic ERG rearrangement data obtained by FISH using an ERG breakapart probe¹¹ yielded similar results. Strong FOXP2 staining was markedly more frequent in tumours with ERG rearrangement (1315/2077 (63%)) as compared with tumours without ERG rearrangement (831/2536 (33%), $p<0.0001$, figure 4B).

Prognostic relevance of FOXP2 expression

Follow-up data were available from 7050 cancers with FOXP2 IHC data. Strong (3+) FOXP2 staining was significantly linked to early biochemical recurrence in all cancers ($p<0.0001$, figure 5A). This association became even more evident in 3543

Figure 1 Representative pictures of FOXP2 immunostaining in prostate cancer and prostate normal tissue. (A) Negative, (B) weak, (C) moderate, (D) strong staining in cancers, (E) cancer (magnified in G) and adjacent normal prostate epithelium (magnified in F) in the same tissue spot (E).

ERG-negative cancers ($p < 0.0001$, figure 5B), but was completely lost in the subset of 2625 ERG fusion-positive tumours ($p = 0.3887$, figure 5C). A multivariate analysis revealed that this association failed to become independent ($p = 0.1033$) from established prognostic risk factors including pT stage, Gleason grade and nodal stage ($p < 0.0001$; each) if all cancers were jointly analysed (table 3).

DISCUSSION

The results of our study demonstrate that high FOXP2 expression is strongly linked to adverse features of the disease in ERG fusion-negative prostate cancers. In particular, FOXP2 overexpression was linked to advanced tumour stage, high Gleason grade, and presence of lymph node metastases and early tumour recurrence.

In this study, FOXP2 was constitutively expressed at high level in the nuclei of basal and secretory cells of normal prostate glands. FOXP1-4 family members act as transcriptional repressors and regulate differentiation of neuronal and immune cells.^{12–14} Thus, our findings are consistent with a general role

of FOXP2 for prostate epithelial differentiation and functioning, including the proliferative basal cells and the differentiated, quiescent secretory cells. The absence of FOXP2 protein in stromal cells of the prostate fits well with results of a previous study reporting relatively low FOXP2 mRNA levels in the prostate.⁷ The stromal component can be substantial in prostate tissue and may have led to a massive dilution of mRNAs derived from prostate epithelium. Other studies reported FOXP2 mRNA expression from most other normal tissues also, with highest levels in ovary, colon, brain, liver and intestine,⁷ as well as developing tissues from lung, heart and gut.¹⁵ Several studies have linked FOXP2 expression to fetal and adult neuronal tissues,¹⁴ where it has been implicated in neuronal differentiation and speech development.⁸

The strong association between lost or reduced FOXP2 expression and favourable tumour phenotype and good prognosis was counterintuitive. It is much more common that the loss of molecular features of the normal prostate epithelium parallels tumour cell dedifferentiation and is rather associated with poor outcome. This for example applies for ALCAM, PTEN,

Table 2 Association between the FOXP2 immunostaining (IHC) result and prostate cancer phenotype

Parameter	n	Evaluable	FOXP2 IHC result				p Value
			Negative (%)	Weak (%)	Moderate (%)	Strong (%)	
All cancers	8,289	6	19	34	41		
Tumour stage							
pT2	5,546	7	21	34	38		<0.0001
pT3a	1,796	5	16	33	46		
pT3b	904	3	14	40	43		
pT4	22	0	5	45	50		
Gleason grade							
<3+3	1,817	8	23	35	34		<0.0001
3+4	4,827	6	19	33	42		
4+3	1,220	4	16	36	45		
>4+4	394	3	13	40	44		
Lymph node metastasis							
N0	4,363	6	18	34	43		<0.0001
N+	429	4	10	40	46		
Surgical margin							
Negative	6,652	6	19	34	41		0.2967
Positive	1,479	6	17	38	46		

E-cadherin or CDKN2A (p16) in prostate cancer.^{16–19} One possible explanation for the unusual scenario, that a normal cell protein all of a sudden becomes oncogenic is that a switch of the cell metabolism has occurred in which the ‘normal cell protein’ obtains a completely different role or function. That FOXP2 has the potential to interfere with pathways that are related to cancer is well known. For example, FOXP2 regulates the expression of a variety of genes involved in tumour-relevant pathways such as WNT, NF- κ B and IGF-1.^{20–21} Moreover, FOXP2 interacts with, and regulates the activity of C-terminal binding protein 1 (CTBP1).²² Overexpression of CTBP1 promotes cell cycle progression and inhibits apoptosis by repressing the expression of known tumour suppressor and apoptosis genes such as PTEN, p16 and BAX.²³ Moreover, that FOXP2 was found overexpressed in lymphoma cells as compared with their normal counterparts is further suggesting that FOXP2 can exert an oncogenic function in vivo.⁷

Our subset analyses in ERG-positive and ERG-negative prostate cancers appear to potentially explain the paradoxical associations of retained high FOXP2 levels with unfavourable tumour features. The most common chromosomal rearrangement known in prostate cancer fuses the androgen responsive TMPRSS2 gene to the ETS family transcription factor ERG gene.²⁴ This alteration occurs in about 50% of prostate cancers and causes high level ERG protein expression and a variety of molecular downstream changes in affected cancers.^{24–27} The TMPRSS2:ERG fusion is the prototype of a number of similar rearrangements resulting in oncogenic activation of ETS genes^{28–31} in prostate cancer, which have led to a molecular subclassification of fusion-negative and fusion-positive prostate cancers. Our data revealed a significant difference in frequency and prognostic impact of FOXP2 expression in fusion-type and non fusion-type prostate cancer. We found that a retained, moderate to strong FOXP2 expression was significantly linked to ERG fusion-positive cancers. Importantly, this association held true for immunohistochemical analysis of ERG expression and for FISH-based detection of ERG breakage, excluding a

Figure 2 Association between FOXP2 immunostaining intensity and cell proliferation as measured by the Ki67 labelling index (Ki67 LI) in (A) all cancers (n=5352), (B) ERG positive cancers (n=2302), and (C) ERG negative cancers (n=2989).

potential IHC-related artificial relationship. Strikingly, almost all adverse features connected to FOXP2 overexpression were limited to the subset of ERG-negative cancers.

This finding argues for biologically distinct consequences of FOXP2 in ERG fusion-negative and ERG fusion-positive cancers. A different role of FOXP2 in ‘fusion-type’ and ‘non fusion-type’ prostate cancer is conceivable. Alternatively, the tumour promoting effect of FOXP2 may be counteracted by ERG. ERG is normally not expressed in the prostate epithelium. Activation of ERG expression by TMPRSS2:ERG gene fusion

Figure 3 Significant associations between FOXP2 immunostaining and Ki67 labelling index (Ki67LI) in tumour subsets of identical Gleason grade.

results in aberrant activation of different signalling cascades in ERG fusion-positive as compared with ERG fusion-negative prostate cancers.^{27 32–34} One of the best known consequences of ERG expression is activation of WNT signalling^{26 27 35} It is tempting to speculate that FOXP2 and ERG, or their target genes, interfere with pathways governing tumour aggressiveness, possibly including the WNT pathway, which is subsequently reflected by the different clinical course in ERG-positive and ERG-negative cancers. The genes or mechanisms mediating this effect remain to be identified.

Indirect evidence for substantial differences on the cell biological effect of FOXP2 depending of the gene sets activated in cancer cells is derived from the significant link of high FOXP2 expression and multiple myeloma pathogenesis.⁷

Figure 4 Association between positive FOXP2 immunostaining and ERG fusion status probed by (A) IHC and (B) FISH analysis. $p < 0.0001$; each.

Figure 5 Association between FOXP2 immunostaining intensity and biochemical recurrence in (A) all cancers ($n=7050$), (B) ERG-negative cancers ($n=3543$) and (C) ERG-positive cancers ($n=2625$).

In summary our study suggests an important role of FOXP2 for prostate cancer development and progression, and suggests biologically different effects in ERG fusion-positive and ERG fusion-negative cancers. In non fusion-type prostate cancer, high FOXP2 expression stratifies a subset of prostate cancers with a particularly poor prognosis.

Acknowledgements We thank Christina Koop, Julia Schumann, Sünje Seekamp and Inge Brandt for excellent technical assistance.

Contributors LS and LB conceived the study, carried out experiments and analysed data. SS, GS, SM performed the pathological review. GS, RS, HS, SM, TS and UM participated in the design of the study, statistical analysis of the data and drafting of the manuscript. All authors were involved in interpreting data, writing the paper and approving the final version of the manuscript. UM is responsible for the overall content as guarantor.

Table 3 COX regression multivariate analysis for the prediction of biochemical recurrence

Parameter	Factor	HR	95% CI	p Value
pT Stage	pT3a vs pT2	2.3	1.9 to 2.8	<0.0001
	pT3b vs pT3a	1.8	1.5 to 2.1	
	pT4 vs pT3b	1.1	0.5 to 2.0	
Gleason	3+4 vs <3+3	1.7	1.2 to 2.5	<0.0001
	4+3 vs 3+4	2.2	1.8 to 2.5	
	>4+4 vs 4+3	1.0	0.8 to 1.2	
pN stage	N+ vs N0	1.7	1.4 to 2.1	<0.0001
FOXP2	Weak vs negative	0.8	0.6 to 1.2	0.1033
	Moderate vs weak	1.2	0.9 to 1.4	
	Strong vs moderate	1.1	0.9 to 1.3	

Take-home message

- The forkhead box transcription factor FOXP2 is abundantly expressed in a broad variety of human tissues. Physiologically, FOXP2 regulates transcriptional programs required for neuronal differentiation, but several studies have also suggested a role in cancer biology.
- Employing immunohistochemistry, we found largely comparable levels of FOXP2 expression in normal and cancerous prostate. Paradoxically, FOXP2 expression was linked to aggressive tumor features, including advanced stage, high Gleason grade, increased proliferation and early biochemical recurrence.
- The adverse effect of FOXP2 expression was limited to prostate cancers lacking TMPRSS2:ERG fusion, suggesting that these cancers may activate pathways that interact with FOXP2 in promoting tumor progression.

Funding This work was supported by the German Research Foundation (DFG SI 572/4-1) and Federal Ministry of Education and Research (BMBF) (FKZ 01GS08189).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Katoh M. Human FOX gene family (Review). *Int J Oncol* 2004;25:1495–500.
- Fox SB, Brown P, Han C, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. *Clin Cancer Res* 2004;10:3521–7.
- Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell* 2010;18:11–22.
- Bignone PA, Banham AH. FOXP3+ regulatory T cells as biomarkers in human malignancies. *Expert Opin Biol Ther* 2008;8:1897–920.
- Teufel A, Wong EA, Mukhopadhyay M, et al. FoxP4, a novel forkhead transcription factor. *Biochim Biophys Acta* 2003;1627:147–52.
- Howarth KD, Blood KA, Ng BL, et al. Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. *Oncogene* 2008;27:3345–59.
- Campbell AJ, Lyne L, Brown PJ, et al. Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. *Br J Haematol* 2010;149:221–30.
- Kang C, Drayna D. Genetics of speech and language disorders. *Annu Rev Genomics Hum Genet* 2011;12:145–64.
- Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. *Prostate* 2010;71:281–8.
- Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. *Clin Cancer Res* 2010;16:1553–60.
- Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. *Clin Cancer Res* 2011;17:5878–88.
- Mercer F, Unutmaz D. The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. *Adv Exp Med Biol* 2009;665:47–59.
- Lalmansingh AS, Karmakar S, Jin Y, et al. Multiple modes of chromatin remodeling by Forkhead box proteins. *Biochim Biophys Acta* 2012;1819(7):707–15.
- Takahashi H, Takahashi K, Liu FC. FOXP genes, neural development, speech and language disorders. *Adv Exp Med Biol* 2009;665:117–29.
- Schroeder DI, Myers RM. Multiple transcription start sites for FOXP2 with varying cellular specificities. *Gene* 2008;413:42–8.
- Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. *Hum Pathol* 2011;42:1946–52.
- Lotan T, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. *Clin Cancer Res* 2011;17:6563–73.
- Gravdal K, Halvorsen OJ, Haukaas SA, et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. *Clin Cancer Res* 2007;13:7003–11.
- Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. *J Clin Oncol* 2007;25:3082–9.
- Yasui H, Hideshima T, Richardson PG, et al. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. *Br J Haematol* 2006;132:385–97.
- Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. *Leukemia* 2009;23:10–24.
- Li S, Weidenfeld J, Morrissey EE. Transcriptional and DNA binding activity of the Foxp1/2/4 family is modulated by heterotypic and homotypic protein interactions. *Mol Cell Biol* 2004;24:809–22.
- Chinnadurai G. The transcriptional corepressor CtBP: a foe of multiple tumor suppressors. *Cancer Res* 2009;69:731–4.
- Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 2005;310:644–8.
- Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 2008;10:177–88.
- Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. *Cancer Res* 2010;70:6735–45.
- Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. *BMC Cancer* 2011;11:507.
- Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. *Clin Cancer Res* 2009;15:6398–403.
- Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. *Cancer Res* 2008;68:7541–9.
- Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. *Cancer Res* 2008;68:7629–37.
- Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. *Nature* 2009;458:97–101.
- Markert EK, Mizuno H, Vazquez A, et al. Molecular classification of prostate cancer using curated expression signatures. *Proc Natl Acad Sci U S A* 2011;108:21276–81.
- Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. *Cancer Cell* 2010;17:415–16.
- Yu J, Mani RS, Cao Q, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. *Cancer Cell* 2010;17:443–54.
- Mochmann LH, Bock J, Ortiz-Tanchez J, et al. Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. *Oncogene* 2011;30:2044–56.